CLINICAL AND HEMODYNAMIC PROFILE AND NEUROHORMONAL INDICATORS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION, DEPENDING ON VASOREACTIVITY RESERVE OF PULMONARY ARTERIES

Clinical and hemodynamic profile and neurohormonal indicators in patients with idiopathic pulmonary hypertension, depending on vasoreactivity reserve of pulmonary arteries. Objective: the main objective of our research work was an evaluation of clinical and hemodynamic profile, neurohormonal indicat...

Full description

Bibliographic Details
Main Authors:	V. M. Paramonov, T. V. Martynyuk, Z. H. Dadacheva, N. M. Danilov, V. P. Masenko, I. Ye. Chazova
Format:	Article
Language:	Russian
Published:	InterMedservice 2016-03-01
Series:	Евразийский Кардиологический Журнал
Subjects:	идиопатическая лёгочная гипертензия острая фармакологическая проба катетеризация правых отделов сердца нейрогуморальные показатели idiopathic pulmonary hypertension acute pharmacological testing right heart catheterization neurohormonal indicators
Online Access:	https://www.heartj.asia/jour/article/view/5658

Similar Items

THE RESULTS OF LONG-TERM PAH-SPECIFIC MONOTHERAPY WITH BOSENTAN IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION
by: V. M. Paramonov, et al.
Published: (2016-06-01)

FEATURES OF CUTANEOUS MICROCIRCULATORY BLOOD FLOW IN PATIENTS WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION ASSESSED BY LASER DOPPLER FLOWMETRY DEPENDING ON VASOREACTIVITY STATUS ON INHALED NITRIC OXIDE
by: E. V. Dolgova, et al.
Published: (2016-06-01)

Corrected orthogonal vectorcardiography in pulmonary hypertension diagnostics
by: E. S. Yurasova, et al.
Published: (2005-12-01)

CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2019-12-01)

THE EFFICACY OF SILDENAFIL THERAPY IN PATIENTS WITH PULMONARY HYPERTENSION OF DIFFERENT ETIOLOGY: INFLUENCE ON THE CLINICAL, FUNCTIONAL, HEMODYNAMIC STATUS, STRUCTURE AND FUNCTION OF THE RIGHT AND LEFT HEART, RIGHT VENTRICULAR-ARTERIAL COUPLING
by: T. V. Martynyuk, et al.
Published: (2017-03-01)

INHALED NITRIC OXIDE: CLINICAL EFFECTS AND INFLUENCE ON THE PROFILE OF INFLAMMATORY MARKERS IN PATIENTS WITH IDIOPATHIC PULMONARY HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01)

ORAL ANTICOAGULANTS IN PATIENTS WITH DIFFERENT FORMS OF PULMONARY ARTERIAL HYPERTENSION, ASPECTS OF THE PROBLEM
by: S. Ye. Gratsianskaya, et al.
Published: (2017-12-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
by: E. A. Rezukhina, et al.
Published: (2021-09-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

COVID-19 pandemic challenges: on the way to overcome obstacles in realization of PAH-specific therapy treatment goals
by: E. A. Rezukhina, et al.
Published: (2021-11-01)

Vasoreactivity testing in pulmonary hypertension associated with congenital heart disease
by: A. A. Shmalts, et al.
Published: (2022-10-01)

EXPERIENCE OF IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS MANAGEMENT IN URAL FEDERAL DISTRICT: FEATURES OFOUTPATIENT-HOSPITAL INTERACTIONS
by: S. V. Shalaev, et al.
Published: (2019-03-01)

Intracardiac and pulmonary hemodynamics and arterial blood gases in patients with chronic stable angina pectoris associated with chronic obstructive pulmonary disease
by: V. A. Nevzorova, et al.
Published: (1970-01-01)

CLINICAL CASE OF COMBINATION THERAPY INCLUDING AMBRIZENTAN IN THE PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: G. A. Movsisyan, et al.
Published: (2017-06-01)

THE ROLE OF RADIATION DIAGNOSTIC TECHNIQUES IN THE DIAGNOSIS OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
by: E. A. Mershina, et al.
Published: (2016-07-01)

LEFT MAIN CORONARY ARTERY COMPRESSION SYNDROME IN PATIENT WITH PULMONARY ARTERIAL HYPERTENSION. FIRST CLINICAL EXPERIENCE
by: A. N. Bykov, et al.
Published: (2018-12-01)

Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report
by: S. A. Musashaykhova, et al.
Published: (2022-12-01)

CLINICAL CASE: THERAPY WITH SILDENAFIL IN THE TREATMENT OF IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2015-12-01)

CARDIOPULMONARY EXCERSISE TESTING IN RISK STRATIFICATION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
by: I. N. Taran, et al.
Published: (2017-12-01)

Anticoagulant Therapy of Acute Pulmonary Embolism with Right Heart Thrombi
by: N. N. Аvdeeva, et al.
Published: (2021-07-01)

APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-06-01)

Nifedipine and losartan effects on endothelial function during acute pharmacological test in arterial hypertension patients with various risk factors
by: M. O. Argunova, et al.
Published: (2008-02-01)

EFFICACY AND SAFETY OF VASOACTIVE BETA-BLOCKERS IN ACUTE PHARMACOLOGICAL TEST IN HYPERTENSIVE PATIENTS OF DIFFERENT AGES
by: O. V. Fedorishina, et al.
Published: (2016-01-01)

CLINICAL FEATURES OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL SYSTEMIC-TO-PULMONARYSHUNTS
by: S. Ye. Gratsianskaya, et al.
Published: (2017-12-01)

CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynyuk, et al.
Published: (2015-12-01)

SUCCESSFUL TREATMENT OF INOPERABLE THROMBOEMBOLIC PULMONARY HYPERTENSION PATIENT WITH SILDENAFIL IN HIGH DOSES
by: Z. H. Dadacheva, et al.
Published: (2014-12-01)

COMPARATIVE CLINICAL CHARACTERISTICS OF PATIENTS WITH VARIOUS FORMS OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE, ACCORDING TO THE CLINICAL CLASSIFICATION
by: S. E. Gratsianskaya, et al.
Published: (2019-12-01)

CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
by: E. A. Devetyarova, et al.
Published: (2018-06-01)

PATHOLOGIC PHYSIOLOGY OF EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: S. N. Avdeev
Published: (2019-05-01)

NUCLEAR IMAGING IN PULMONARY HYPERTENSION
by: V. B. Sergienko, et al.
Published: (2017-03-01)

Heart and pulmonary artery remodeling association with various levels of natriuretic peptides and renin-angiotensin-aldosterone system activation in patients with pulmonary hypertension of various etiology
by: Yu. A. Andreeva, et al.
Published: (2008-12-01)

Tissue myocardial Doppler echocardiography in the assessment of right ventricular function among patients with pulmonary hypertension of various aetiology
by: Yu. A. Andreeva, et al.
Published: (2010-04-01)

CLINICAL CASE: CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN A CHILD
by: D. J. Sadykova, et al.
Published: (2017-03-01)

About choosing a vasodilator for vasoreactivity tests in heart transplant candidates
by: А. Е. Баутин, et al.
Published: (2015-10-01)

EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2020)
by: I. E. Chazova, et al.
Published: (2021-03-01)

PULMONAR.Y ARTERIAL HYPERTENSION ASSOCIATED WITH A SYSTEMIC SCLEROSIS: REVIEW OF LITERATURE
by: N. N. Yudkina, et al.
Published: (2015-12-01)

OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS
by: T. V. Martynyuk, et al.
Published: (2017-06-01)

Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension associated with congenital heart defects in adults (2021)
by: I. E. Chazova, et al.
Published: (2022-05-01)

Calculation of hemodynamics by the Fick method in pulmonary hypertension associated with congenital heart defects
by: A. A. Shmalts, et al.
Published: (2022-05-01)

New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
by: N. V. Ilyin, et al.
Published: (2019-12-01)